



## **TScan Therapeutics to Participate in the 13th Annual Webbush PacGrow Healthcare Conference**

August 3, 2022

WALTHAM, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David P. Southwell, President and Chief Executive Officer, will participate in a virtual panel discussion titled "A View to a Kill(er Cell)" at the 13<sup>th</sup> Annual Webbush PacGrow Healthcare Conference on Wednesday, August 10, 2022 at 1:10 p.m. ET.

A webcast of the panel discussion will be available on the "[Events and Presentations](#)" section of the Company's website at [ir.tscan.com](http://ir.tscan.com). An archived replay of the webcast will be available on the Company's website for 30 days following the event.

### **About TScan Therapeutics, Inc.**

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company's lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after hematopoietic stem cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company's repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types in order to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.

### **Contacts:**

Heather Savelle  
TScan Therapeutics, Inc.  
VP, Investor Relations  
857-399-9840  
[hsavelle@tscan.com](mailto:hsavelle@tscan.com)

Joyce Allaire  
LifeSci Advisors, LLC  
Managing Director  
617-435-6602  
[jallaire@lifesciadvisors.com](mailto:jallaire@lifesciadvisors.com)